ARQT

14.81

2.31% -0.35

Dopo l'orario di chiusura: 15.46 0.65 +4.39%

Arcutis Biotherapeutics Inc (ARQT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARQT Giù? Forum Previsione

Precedente Chiudi:

$15.16

Aprire:

$15.12

Volume 24 ore:

1.03M

Relative Volume:

0.49

Capitalizzazione di mercato:

$1.76B

Reddito:

$59.61M

Utile/perdita netta:

$-262.14M

Rapporto P/E:

-3.7781

EPS:

-3.92

Flusso di cassa netto:

$-247.49M

1 W Prestazione:

+2.14%

1M Prestazione:

+20.31%

6M Prestazione:

+38.93%

1 anno Prestazione:

+33.91%

Intervallo 1D:

$14.63

$15.40

Intervallo di 1 settimana:

$13.80

$16.09

Portata 52W:

$6.99

$16.20

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Nome

Arcutis Biotherapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (679)

Telefono

805-418-5006

Indirizzo

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Dipendente

342

Cinguettio

@ArcutisBio

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

ARQT's Discussions on Twitter

Confronta ARQT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARQT Arcutis Biotherapeutics Inc	14.81	1.76B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-28	Iniziato	Jefferies	Buy
2024-01-03	Aggiornamento	Mizuho	Neutral → Buy
2023-10-26	Downgrade	Mizuho	Buy → Neutral
2023-10-13	Downgrade	Goldman	Buy → Neutral
2022-09-07	Iniziato	Needham	Buy
2022-03-17	Iniziato	Goldman	Buy
2021-06-30	Iniziato	Mizuho	Buy
2021-05-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Aggiornamento	Goldman	Neutral → Buy
2020-10-08	Iniziato	Truist	Buy
2020-02-25	Iniziato	Cantor Fitzgerald	Overweight
2020-02-25	Iniziato	Cowen	Outperform
2020-02-25	Iniziato	Goldman	Neutral
2020-02-25	Iniziato	Guggenheim	Buy

Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

Mar 12, 2025

Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha

Mar 12, 2025

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World

Mar 12, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World

Mar 12, 2025

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada

Mar 11, 2025

Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa

Mar 11, 2025

Mar 10, 2025

Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR

Mar 10, 2025

Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World

Mar 10, 2025

Mar 09, 2025

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St

Mar 09, 2025

Mar 07, 2025

Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks

Mar 07, 2025

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times

Mar 07, 2025